Stay updated on MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Sign up to get notified when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    The record presents the study’s treatment arms, eligibility criteria, outcome measures, locations, status, and study documents for a Phase 2 melanoma trial combining pembrolizumab with targeted therapy.
    Difference
    59%
    Check dated 2026-11-08T01:59:27.000Z thumbnail image
  2. Check
    14 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision label changed from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-31T22:10:05.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A site-wide banner announces the NIH terminology transition from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-24T22:28:21.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.1 to v3.7.2; the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-17T22:40:00.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T22:24:58.000Z thumbnail image
  6. Check
    56 days ago
    Change Detected
    Summary
    The page now renders a 403 Forbidden error page instead of the study content, indicating the record is currently inaccessible on ClinicalTrials.gov.
    Difference
    20%
    Check dated 2026-09-19T20:54:32.000Z thumbnail image

Stay in the know with updates to MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the MAPK Therapy + Pembrolizumab in Melanoma Clinical Trial page.